CD276 expression is associated with poor prognosis, likely due to its role in inhibiting the activity of T cells and NK cells (24–26), thereby providing a rationale for targeting this antigen in therapeutic strategies aimed at enhancing anti-tumor immunity. This evidence concerns the gene CD276 and neoplasm.